RxDoctor Payments Data

Jonathan Graf, MD

Internal Medicine · San Francisco, CANPI 1487660635

Payments from drug & device makers

$342,613in general payments, 2019–2025

Across 57 payments — averaging $6010.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Navidea Biopharmaceuticals, Inc.$165K
  • Amgen$126K
  • AbbVie$48K
  • Gilead$4K
  • Eli Lilly$125
  • E.r. Squibb & Sons, L.L.C.$125
  • plus $298 from 5 others

What the payments were for

  • Consulting fees$19,60086%
  • Travel & lodging$1,8158%
  • Food & beverage$1,1225%
  • Education$1531%

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$342,613 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$23,703
Medicare patients
55
Services billed
190

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cimzia (2 Pack)Certolizumab Pegol70$568,963
Humira PenAdalimumab58$376,239
Enbrel SureclickEtanercept48$346,887
EnbrelEtanercept24$174,959
RinvoqUpadacitinib19$147,656
OrenciaAbatacept22$146,046
HumiraAdalimumab12$81,197
ActemraTocilizumab12$25,224
VemlidyTenofovir Alafenamide11$17,978
RasuvoMethotrexate/Pf25$17,328
MethotrexateMethotrexate Sodium162$5,928
Sulfasalazine75$3,074
Hydroxychloroquine Sulfate81$3,069
Leflunomide45$2,204
Prednisone233$1,659

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Cimzia (2 Pack)$48$568,96370 claims
AbbVieRinvoq, Humira$47,742$228,85331 claims
AmgenEnbrel$125,898$174,95924 claims
E.r. Squibb & Sons, L.L.C.Orencia$125$146,04622 claims
Genentech, Inc.Actemra$53$25,22412 claims
GileadVemlidy$3,500$17,97811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.

Other internal medicine in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →